» Articles » PMID: 37132142

Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review

Overview
Date 2023 May 3
PMID 37132142
Authors
Affiliations
Soon will be listed here.
Abstract

This narrative state-of-the-art review paper describes the progress in the understanding and treatment of Posttraumatic Stress Disorder (PTSD). Over the last four decades, the scientific landscape has matured, with many interdisciplinary contributions to understanding its diagnosis, etiology, and epidemiology. Advances in genetics, neurobiology, stress pathophysiology, and brain imaging have made it apparent that chronic PTSD is a systemic disorder with high allostatic load. The current state of PTSD treatment includes a wide variety of pharmacological and psychotherapeutic approaches, of which many are evidence-based. However, the myriad challenges inherent in the disorder, such as individual and systemic barriers to good treatment outcome, comorbidity, emotional dysregulation, suicidality, dissociation, substance use, and trauma-related guilt and shame, often render treatment response suboptimal. These challenges are discussed as drivers for emerging novel treatment approaches, including early interventions in the Golden Hours, pharmacological and psychotherapeutic interventions, medication augmentation interventions, the use of psychedelics, as well as interventions targeting the brain and nervous system. All of this aims to improve symptom relief and clinical outcomes. Finally, a phase orientation to treatment is recognized as a tool to strategize treatment of the disorder, and position interventions in step with the progression of the pathophysiology. Revisions to guidelines and systems of care will be needed to incorporate innovative treatments as evidence emerges and they become mainstream. This generation is well-positioned to address the devastating and often chronic disabling impact of traumatic stress events through holistic, cutting-edge clinical efforts and interdisciplinary research.

Citing Articles

Telomere Dynamics in Post-Traumatic Stress Disorder: A Critical Synthesis.

Rajkumar R Biomedicines. 2025; 13(2).

PMID: 40002919 PMC: 11853385. DOI: 10.3390/biomedicines13020507.


Three-Month Durability of Bilateral Two-Level Stellate Ganglion Blocks in Patients with Generalized Anxiety Disorder: A Retrospective Analysis.

Mulvaney S, Dineen K, Mahadevan S, Desronvilles Jr R, Rae Olmsted K Brain Sci. 2025; 15(2).

PMID: 40002521 PMC: 11853295. DOI: 10.3390/brainsci15020188.


Shared genetic risk and causal associations between Post-traumatic stress disorder and migraine with antithrombotic agents and other medications.

Bainomugisa C, Bruenig D, Sutherland H, Griffiths L, Nyholt D, Mehta D Neurobiol Stress. 2025; 34:100703.

PMID: 39898008 PMC: 11786899. DOI: 10.1016/j.ynstr.2024.100703.


Veterans' experiences of somatic experiencing and prolonged exposure therapies for post-traumatic stress disorder: A qualitative analysis.

Harwood-Gross A, Elias S, Lerner K, Nacasch N, Lawi C, Brom D Psychol Psychother. 2025; 98(1):175-192.

PMID: 39807650 PMC: 11823315. DOI: 10.1111/papt.12570.


Chronobiology in Paediatric Neurological and Neuropsychiatric Disorders: Harmonizing Care with Biological Clocks.

Giannotta G, Ruggiero M, Trabacca A J Clin Med. 2025; 13(24.

PMID: 39768659 PMC: 11678831. DOI: 10.3390/jcm13247737.


References
1.
Bradlow R, Berk M, Kalivas P, Back S, Kanaan R . The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders. CNS Drugs. 2022; 36(5):451-482. PMC: 9095537. DOI: 10.1007/s40263-022-00907-3. View

2.
Cloitre M, Petkova E, Wang J, Lu Lassell F . An examination of the influence of a sequential treatment on the course and impact of dissociation among women with PTSD related to childhood abuse. Depress Anxiety. 2012; 29(8):709-17. DOI: 10.1002/da.21920. View

3.
Murphy D, Smith K . Treatment Efficacy for Veterans With Posttraumatic Stress Disorder: Latent Class Trajectories of Treatment Response and Their Predictors. J Trauma Stress. 2018; 31(5):753-763. PMC: 6456014. DOI: 10.1002/jts.22333. View

4.
Bryant R, Nickerson A, Creamer M, ODonnell M, Forbes D, Galatzer-Levy I . Trajectory of post-traumatic stress following traumatic injury: 6-year follow-up. Br J Psychiatry. 2015; 206(5):417-23. DOI: 10.1192/bjp.bp.114.145516. View

5.
Kraehenmann R, Preller K, Scheidegger M, Pokorny T, Bosch O, Seifritz E . Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biol Psychiatry. 2014; 78(8):572-81. DOI: 10.1016/j.biopsych.2014.04.010. View